We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
TRADEMARK (TO BE ADVISED) Merck Sharp & Dohme (Australia) Pty Ltd
Product name
TRADEMARK (TO BE ADVISED)
Accepted date
Mar-2025
Active ingredients
clesrovimab
Proposed indication
Clesrovimab is used to prevent respiratory syncytial virus (RSV) in newborns and infants who are born during or entering their first RSV season.
Application type
A (new medicine)
Publication date
Mar-2025